NCT01475292

A Study to Investigate How Safe and Well Tolerated RV568 is in Patients With Chronic Obstructive Pulmonary Disease (COPD)

A Randomised, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Safety and Tolerability of Treatment With Repeat Doses of Inhaled RV568 in Patients With COPD

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 30 (actual)
• Sponsor: Respivert Ltd · Industry
• Sex: All
• Age: 40 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

RV568 is being developed as a possible treatment of diseases such as smoking related lung disease (also known as Chronic Obstructive Pulmonary Disease - COPD) and asthma. The main purpose of this study is to examine the safety of RV568 in COPD patients. Two dose strengths of RV568 and a placebo will be tested in this study, which will be given by inhaling a liquid suspension from a nebuliser once a day for 2 weeks.

Conditions

• Chronic Obstructive Pulmonary Disease

Interventions

Type	Name	Description
DRUG	RV568	RV568 50 ug administered via a nebuliser once daily for 14 days
DRUG	RV568	RV568 100 ug administered via a nebuliser once daily for 14 days
DRUG	Placebo	Placebo administered via a nebuliser once daily for 14 days

Timeline

• Start date: 2011-11-01
• Primary completion: 2012-04-01
• Completion: 2012-04-01
• First posted: 2011-11-21
• Last updated: 2012-05-03

Locations

2 sites across 1 country: United Kingdom